Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma

Journal of the American Academy of Dermatology

Volumn 49, Issue 4, 2003, Pages 567-588

  Perrott, Ronald E ^a   Glass, L Frank ^a,b   Reintgen, Douglas S ^c   Fenske, Neil A ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c MDC 19 ^*

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN SERUM ALBUMIN TC 99M; RECOMBINANT ALPHA2B INTERFERON; TECHNETIUM SULFUR COLLOID TC 99M;

BONE MARROW SUPPRESSION; CANCER STAGING; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; DIAPHORESIS; DRUG FATALITY; ELECTIVE SURGERY; FATIGUE; FEVER; FLU LIKE SYNDROME; HIGH RISK PATIENT; HUMAN; LIVER TOXICITY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHATIC SYSTEM; LYMPHOSCINTIGRAPHY; MALAISE; MELANOMA; MORBIDITY; PATIENT SELECTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE;

EID: 0141644374     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/S0190-9622(03)02136-4     Document Type: Review

References (113)

1. Shaw HM, Balch CM, Soong SJ, Milton GW, McCarthy WH. Prognostic histopathological factors in malignant melanoma. Pathology 1985;17:271-4.
2. Balch CM, Soong SJ, Milton GW, Shaw HM, McGovern VJ, Murad TM, et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama USA, and New South Wales, Australia. Ann Surg 1982;196:677-84.
3. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma: III, prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 1981;193:377-88.
4. Buzaid AC, Ross MI, Balch CM, Soong SJ, McCarthy WH, Tinoco L, et al. Critical analysis of the current American joint committee on cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997;15:1039-51.
5. Walsh P, Gibbs P, Gonzalez R. Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease. J Am Acad Dermatol 2000;42:480-9.
6. Snow H: Melanotic cancerous disease. Lancet 1892;2:872.
7. Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Nieweg OE, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial; multicenter selective lymphadenectomy trial group. Ann Surg 1999;230:453-63.
8. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early-stage melanoma. Arch Surg 1992;127:392-9.
9. Reintgen D, Cruse CW, Wells K, Berman C, Fenske N, Glass F, et al. The orderly progression of melanoma nodal metastases. Ann Surg 1994;220:759-67.
10. Thompson JF, McCarthy WH, Bosch CM, O'Brien CJ, Quin MJ, Paramaesvaran S, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995;5:255-60.
11. Wong JH,Cagle LA, Morton DL. Lymphatic drainage of skin to a sentinel lymph node in a feline model. Ann Surg 1991;214:637-41.
12. Balch CM. The role of elective lymph node dissection in melanoma: rationale, results, and controversies. J Clin Oncol 1988; 6:163-72.
13. Piepkorn M, Weinstock MA, Barnhill RL. Theoretical and empirical arguments in relation to elective lymph node dissection for melanoma. Arch Dermatol 1997;133:995-1002.
14. Lyons JH III, Cockerell CJ. Elective lymph node dissection for melanoma. J Am Acad Dermotol 1994;30:467-80.
15. Milton GW, Shaw HM, McCarthy WH, Pearson L, Balch CM, Soong SJ. Prophylactic lymph node dissection in clinical stage 1 cutaneous malignant melanoma: results of surgical treatment in 1,319 patients. Br J Surg 1982;69:108-11.
16. Reintgen DS, Cox EB, McCarty KS, Vollmer RT, Seigler HF. Efficacy of elective lymph node dissection in patients with intermediate thickness melanoma. Ann Surg 1983;198:379-85.
17. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes: analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 1991;214:491-9.
18. Kim SH, Garcia C, Rodriquez J, Coit DG. Prognosis of thick cutaneous melanoma. J Am Coll Surg 1999;188:241-7.
19. Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (≥ 4 mm) primary melanoma. Ann Surg Oncol 2000; 7:160-5.
20. Salti GI, Kansagra A, Warso MA, Ronan SG, Das Gupta TK. Clinical node-negative thick melanoma. Arch Surg 2002;137:291-5.
21. Thompson JF, Shaw HM. The prognosis of patients with thick primary melanomas: is regional lymph node status relevant, and does removing positive regional nodes influence outcome? Ann Surg Oncol 2002;9:719-22.
22. Essner R, Chung MH, Bleicher R, Hsueh E, Wanek L, Morton DL. Prognostic implications of thick (≥ 4 mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol 2002;9:754-61.
23. Veronesi U, Adamus J, Bandiera DC, Brennhovd IO, Caceres E, Cascinelli N, et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med 1977;297:627-30.
24. Veronesi U, Adamus J, Bandiera DC, Brennhovd IO, Caceres E, Cascinelli N, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982;49:2420-30.
25. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomized trial. Lancet 1998; 351:793-6.
26. Sim FH, Taylor WF, Ivins JC, Pritchard DJ, Soule EH. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma: preliminary results. Cancer 1978;41:948-56.
27. Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 1986;61:697-705.
28. Balch CM, Soong SJ, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, et al. Efficacy of an elective regional lymph node dissection of 1-4 mm thick melanoma for patients 60 years of age and younger. Ann Surg 1996;224:255-63.
29. Balch CM, Soong S, Ross MI, Urist MM, Karakousis CP, Temple WJ, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm): intergroup melanoma trial. Ann Surg Oncol 2000;7:87-97.
30. Reintgen DS. Emerging evidence for a survival benefit associated with regional lymph node dissection for melanoma. Ann Surg Oncol 2000;7:75-6.
31. Norman J, Cruse CW, Espinosa C, Cox C, Berman C, Clark R, et al. Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma. Am J Surg 1991;162:432-7.
32. Stankard C, Cruse CW, Cox C, Wells KE, King J, Reintgen DS. The concept of lymph node dissections in patients with malignant melanoma. Ann Plast Surg 1992;28:33-8.
33. Ross M, Reintgen DS, Balch C. Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 1993;9:219-23.
34. Ingvar C, Erichsen C, Jonsson PE. Morbidity following prophylactic and therapeutic lymph node dissection for melanoma-a comparison. Tumori 1984;70:529-33.
35. Urist MM, Maddox WA, Kennedy JE, Balch CM. Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients. Cancer 1983;51:2152-6.
36. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng C, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-83.
37. Krag DN, Meijer SJ, Weaver DL, Loggie BW, Harlow SP, Tanabe KK, et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg 1995;130:654-8.
38. Lingam MK, Mackie RM, McKay AJ. Intraoperative identification of sentinel lymph node in patients with malignant melanoma. Br J Cancer 1997;75:1505-8.
39. Bostick P, Essner R, Glass E, Kelley M, Sarantou T, Foshag LJ, et al. Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. Arch Surg 1999;134:43-9.
40. Leong SP, Steinmetz I, Habib FA, McMillan A, Gans JZ, Allen RE, et al. Optimal selective sentinel lymph node dissection in primary malignant melanoma. Arch Surg 1997;132:666-72.
41. Albertini JJ, Cruse CW, Rapaport D, Wells K, Ross M, DeConti R, et al. Intraoperative radiolymphoscintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 1996;223:217-24.
42. Morton DL, Wen DR, Foshag LJ, Essner R, Cochran A. Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck. J Clin Oncol 1993;11:1751-6.
43. Jansen L, Nieweg OE, Peterse JL, Hoefnagel CA, Olmos RA, Kroon BB. Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg 2000;87:484-9.
44. Morton DL, Chan AD. Current status of intraoperative lymphatic mapping and sentinel lymphadenectomy for melanoma: is it standard of care? J Am Coll Surg 1999;189:214-23.
45. Robinson DS, Sample WF, Fee HJ, Holmes C, Morton DL. Regional lymphatic drainage in primary malignant melanoma of the trunk determined by colloidal gold scanning. Surg Forum 1977;28:147-8.
46. Reintgen D. Lymphatic mapping and sentinel node harvest for malignant melanoma. J Surg Oncol 1997;66:277-81.
47. Cascinelli N, Belli F, Santinami M, Fait V, Testori A, Ruka W, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO melanoma program experience. Ann Surg Oncol 2000;7:469-74.
48. Glass FL, Cottam JA, Reintgen DS, Fenske NA. Lymphatic mapping and sentinel node biopsy in the management of high-risk melanoma. J Am Acad Dermatol 1998;39:603-10.
49. Norman J, Wells K, Kearney R, Cruse CW, Berman C, Reintgen D. Identification of lymphatic drainage basin patients with cutaneous melanoma. Semin Surg Oncol 1993;9:224-7.
50. Mudun A, Murray DR, Herda SE, Eshima D, Shattuck LA, Vansant JP,et al. Early stage melanoma: lymphoscintigraphy, reproducibility of sentinel node detection and effectiveness of the intraoperative gamma probe. Radiology 1996;199:171-5.
51. Alex JC, Krag DN. Gamma-probe guided localization of lymph nodes. Surg Oncol 1993;2:137-43.
52. Alex JC, Weaver DL, Fairbank JT, Rankin BS, Krag DN. Gamma-probe-guided lymph node localization in malignant melanoma. Surg Oncol 1993;2:303-8.
53. Glass LF, Messina JL, Cruse W, Wells K, Rapaport D, Miliotes G, et al. The use of intraoperative radiolymphoscintigraphy for sentinel node biopsy in patients with malignant melanoma. Dermatol Surg 1996;22:715-20.
54. McMasters KM, Reintgen DS, Ross MI, Wong SL, Gershenwald JE, Krag DN, et al. Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed? Ann Surg Oncol 2001;8:192-7.
55. Carlson GW, Murray DR, Thourani V, Hestley A, Cohen C. The definition of the sentinel lymph node in melanoma based on radioactive counts. Ann Surg Oncol 2002;9:929-33.
56. Morton DL, Bostick PJ. Will the true sentinel node please stand? Ann Surg Oncol 1999;6:12-4.
57. Coit DG. The "true" sentinel lymph node: in search of an operational definition ofa biological phenomenon. Ann Surg Oncol 2001;8:187-9.
58. Albo D, Wayne JD, Hunt KK, Rahlfs TF, Singletary SE, Ames FC, et al. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg 2001;182:393-8.
59. Cimmino VM, Brown AC, Szocik JF, Pass HA, Moline S, De SK, et al. Allergic reactions to isosulfan blue during sentinel node biopsy-a common event. Surgery 2001;130:439-42.
60. Messina JL, Glass LF, Cruse CW, Berman C, Ku NK, Reintgen DS. Pathologic examination of the sentinel lymph node in malignant melanoma. Am J Surg Pathol 1999;23:686-90.
61. Li W, Stall A, Shivers SC, Lin J, Haddad F, Messina J, et al. Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg 2000;231:795-803.
62. Gershenwald JE, Colome MI, Lee JE, Mansfield PF, Tseng C, Lee JJ, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998;16:2253-60.
63. Wang X, Heller R, VanVoorhis N, Cruse CW, Glass F, Fenske N, et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994;220:768-74.
64. Shivers SC, Wang X, Li W, Joseph E, Messina J, Glass LF, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998;280:1410-5.
65. Bostick PJ, Morton DL, Turner RR, Huynh KT, Wang HJ, Elashoff R, et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 1999;17:3238-44.
66. Blaheta HJ, Ellwanger U, Schittek B, Sotlar K, Maczey E, Breuninger H, et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol 2000;114:637-42.
67. Wrightson WR, Wong SL, Edwards MJ, Chao C, Conrad AJ, Albrecht J, et al. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of nonsentinel nodes following completion lymphadenectomy for melanoma. J Surg Res 2001;98:47-51.
68. Tanis PJ, Boom RP, Koops HS, Faneyte IF, Peterse JL, Nieweg OE, et al. Frozen section investigation of the sentinel node in malignant melanoma and breast cancer. Ann Surg Oncol 2001;8:222-6.
69. Stojadinovic A, Allen PJ, Clary BM, Busam KJ, Coit DG. Value of frozen-section analysis of sentinel lymph nodes for primary cutaneous malignant melanoma. Ann Surg 2002;235:92-8.
70. Koopal SA, Tiebosch AT, Piers DA, Plukker JT, Koops HS, Hoekstra HJ. Frozen section analysis of sentinel lymph nodes in melanoma patients. Cancer 2000;89:1720-5.
71. Gibbs JF, Huang PP, Zhang PJ, Kraybill WG, Cheney R. Accuracy of pathologic techniques for the diagnosis of metastatic melanoma in sentinel lymph nodes. Ann Surg Oncol 1999;6;699-704.
72. Creager AJ, Shiver SA, Shen P, Geisinger KR, Levine EA. Intraoperative evaluation of sentinel lymph nodes for metastatic melanoma by imprint cytology. Cancer 2002;94:3016-22.
73. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19: 3635-48.
74. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American joint committee on cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.
75. Houghton A, Coit D, Bloomer W, Buzaid A, Chu D, Eisenburgh B, et al. NCCN melanoma practice guidelines: national comprehensive cancer network. Oncology 1998;12:153-77.
76. Rhee HQ, Colorado K, Perrott R, Dessureault S, Glass LF, Messina JL, et al. Sentinel lymph node biopsy in patients with "thin" melanomas (0. 76 - 1.0 mm). Poster and discussion session presented at: 60th Annual Meeting of the American Academy of Dermatology; February 22-27, 2002; New Orleans, LA.
77. Finley JW, Gibbs JF, Rodriguez LM, Letourneau R, Driscoll D, Kraybill W. Pathologic and clinical features influencing outcome of thin cutaneous melanoma: correlation with newly proposed staging system. Am Surg 2000;66:527-32.
78. Bedrosian I, Faries M,Guerry D, Elenitsas R, Schuchter L, Mick R, et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (≤1 mm) with vertical growth phase. Ann Surg Oncol 2000;7:262-7.
79. Joseph E, Brobeil A, Glass F, Glass J, Messina J, DeConti R, et al. Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes. Ann Surg Oncol 1998;5:119-25.
80. Haddad F, Stall A, Messina J, Brobeil A, Ramnath E, Glass L, et al. The progression of melanoma nodal metastasis is dependent on tumor thickness of the primary lesion. Ann Surg Oncol 1999; 6:144-9.
81. Muller M, van Leeuwen P, van Diest P, Vuylsteke R, Pijpers R, Meijer S. No indication for performing sentinel node biopsy in melanoma patients with a Breslow thickness of less than 0.9 mm. Melanoma Res 2001;11:303-7.
82. Kelly MC, Ollila DW, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for melanoma. Semin Surg Oncol 1998;14:283-90.
83. Rees W, Robinson D, Holmes E, Morton D. Altered lymphatic drainage following lymphadenectomy. Cancer 1980;45:3045-9.
84. Kelemen P, Essner R, Foshag L, Morton D. Lymphatic mapping and sentinel lymphadenectomy afterwide local excision of primary melanoma. J Am Coll Surg 1999;189:247-52.
85. Karakousis C, Grigoropoulos P. Sentinel node biopsy before and after wide excision of the primary melanoma. Ann Surg Oncol 1999;6:785-9.
86. McCready DR, Ghazarian DM, Hershkop MS, Walker JA, Ambus U, Quirt IC. Sentinel lymph-node biopsy after previous wide local excision for melanoma. Can J Surg 2001;44:432-4.
87. Cochran A, Balda B, Starz H, Bachter D, Krag D, Cruse C, et al. The Augsburg consensus: techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer 2000;89:236-41.
88. Landi G, Polverelli M, Moscatelli G, Morelli R, Landi C, Fiscelli O, et al. Sentinel lymph node biopsy in patients with primary cutaneous melanoma: study of 455 cases. J Eur Acad Dermatol Venereol 2000;14;35-45.
89. Essner R, Conforti A, Kelley MC, Wanek L, Stern S, Glass E, et al. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol 1999;6: 442-9.
90. Bachter D, Michl C, Buchels H, Vogt H, Balda BR. The predictive value of the sentinel lymph node in malignant melanomas. Recent Results Cancer Res 2001;158:129-36.
91. Clary BM, Brady MS, Lewis JJ, Coit DG. Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg 2001;233:250-8.
92. Balch CM, Ross MI. Sentinel lymphadenectomy for melanoma-is it a substitute for elective lymphadenectomy? Ann Surg Oncol 1999;6:416-7.
93. Warso MA, Das Gupta TK. Melanoma recurrence in a previously dissected lymph node basin. Arch Surg 1994;129:252-5.
94. McMasters KM, Reintgen DS, Ross MI, Gershenwald JE, Edwards MJ, Sober A, et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol 2001;19:2851-5.
95. Otley CC, Zitelli JA. Review of sentinel lymph node biopsy and systemic interferon for melanoma: promising but investigation modalities. Dermatol Surg 2000;26:177-80.
96. Thomas JM, Patocskai EJ. The argument against sentinel node biopsy for malignant melanoma: its use should be confined to patients in clinical trials. BMJ 2000;321:3-4.
97. Medalie N, Ackerman AB. Sentinel lymph node biopsy has no benefit for patients with primary cutaneous melanoma: an assertion based on comprehensive, critical analysis. Dermatopathology: Practical & Conceptual 2003;9(1) www.derm101.com.
98. Spitler LE. Adjuvant therapy of melanoma. Oncology 2002;16: 40-8.
99. Sabel MS, Sondak VK. Tumor vaccines: a role in preventing recurrence in melanoma? Am J Clin Dermatol 2002;3:609-16.
100. Eggermont AM, Gore M. European approach to adjuvant treatment of intermediate- and high-risk malignant melanoma. Semin Oncol 2002;29:382-8.
101. Cascinelli N, Belli F, Mackie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomized trial. Lancet 2001;358:866-9.
102. Grobb JJ, Dreno B, de la Salmoniere P, Delaunay M, Cupissol D, Guillot B, et al. Randomized trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases: French cooperative group on melanoma. Lancet 1998;351:1905-10.
103. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial EST 1684. J Clin Oncol 1996;14:7-17.
104. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/ S9111/C9190. J Clin Oncol 2000;18:2444-58.
105. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80.
106. Cherpelis BS, Haddad F, Messina J, Cantor AB, Fitzmorris K, Reintgen DS, et al. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas. J Am Acad Dermatol 2001;44:762-6.
107. Heaton KM, Sussman JJ, Gershenwald JE, Lee JE, Reintgen DS, Mansfield PF, et al. Surgical margins and prognostic factors in patients with thick (> 4 mm) primary melanoma. Ann Surg Oncol 1998;5:322-8.
108. Slingluff CL, Stidham KR, Ricci WM, Stanley WE, Seigler HF. Surgical management of regional lymph nodes in patients with melanoma: experience with 4682 patients. Ann Surg 1994;219:120-30.
109. Zettersten E, Sagebiel RW, Miller JR, Tallapureddy S, Leong SP, Kashani-Sabet M. Prognostic factors in patients with thick cutaneous melanoma (> 4 mm). Cancer 2002;94:1049-56.
110. Coit D, Sauven P, Brennan M. Prognosis of thick cutaneous melanoma of the trunk and extremity. Arch Surg 1990;125:322-6.
111. Connelly TJ. Lymphatic mapping and sentinel lymph node biopsy. J Am Acad Dermatol 2002;46:640.
112. Reintgen DS, Cruse CW, Glass F, Fenske N. In support of sentinel node biopsy as a standard ofcare for patients with malignant melanoma. Dermatol Surg 2000;26:1070-2.
113. McMasters KM, Sondak VK, Lotze MT, Ross MI. Recent advances in melanoma staging and therapy. Ann Surg Oncol 1999;6:467-75.